Navigation Links
Cancer Prevention Pharmaceuticals, Inc. Announces Appointment of Jon S. Saxe to its Board of Directors

TUCSON, Ariz., July 23, 2015 /PRNewswire/ -- Cancer Prevention Pharmaceuticals, Inc. (CPP) today announced that Jon S. Saxe has joined its Board of Directors.

Saxe brings to CPP many years of experience from the biotechnology, pharmaceutical and venture capital industries.  He has served as a director of more than 25 companies and currently is a director of several biotechnology companies, including: SciClone Pharmaceuticals (NASDAQ: SCLN), where he is chairman; DURECT Corporation (NASDAQ: DRRX); as well as a number of private companies. He was president of PDL BioPharma (formerly Protein Design Labs), and also was president and CEO of Synergen, a biotechnology company purchased by Amgen.

Prior to his work at biotech companies Saxe was vice president of licensing and corporate development and head of patent law for Hoffmann-LaRoche Inc., where he worked for 29 years.  

Saxe received a B.S.ChE from Carnegie Mellon University, a J.D. from George Washington University School of Law, and a LL.M. from New York University School of Law.

"We are honored and excited to have Jon Saxe join our board," said Jeff Jacob, chairman of CPP's Board of Directors.  "His broad knowledge of the industry and years of experience both as an executive and in corporate governance will serve CPP well as it continues to grow in the coming years.  The other members of the board and I are very much looking forward to working with Jon."

About Cancer Prevention Pharmaceuticals, Inc. (CPP)

CPP is developing therapeutics that reduce the risk of cancer.  CPP's approach has been used with great success in other disease categories such as cardiovascular, neurovascular and infectious disease.  Agents that target pre-disease states have helped reduce death rates from these conditions by 50%-70% over the past 30 years.  Just as these other prevention therapies represent the largest-selling drug classes on the market today, CPP believes there is even more potential for therapies that reduce the risk of cancer.  CPP is sponsoring a large Phase III trial in colon cancer survivors and a Phase III trial for Familial Adenomatous Polyposis (FAP), an orphan disease that causes hundreds-to-thousands of colon polyps and has a 100% risk of colon cancer unless treated by surgical removal of the colon/rectum.  CPP is also working collaboratively with non-profit groups to support clinical trials in the childhood cancer neuroblastoma, for the prevention of relapse.  Additional information on CPP is available at


SOURCE Cancer Prevention Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
3. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
4. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
5. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
6. Cancer Vaccine Partnering Terms and Agreements
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
8. RAD Technology Medical Systems Delivers Innovative Time Saving Modular Construction At New Swedish Cancer Institute Facility
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Puerto Ricos Caribbean Imaging and Radiation Therapy Center Orders Elektas New Versa HD System for Treatment of Cancer Patients
11. New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
Post Your Comments:
(Date:9/15/2018)... ... September 14, 2018 , ... Today, ... showcases the innovative work being done within rare diseases research diagnostics and highlights ... with rare diseases. , The print component of "Rare Diseases" ...
(Date:9/15/2018)... CEDAR POINT, N.C. (PRWEB) , ... September 14, 2018 , ... ... is now on the map thanks to Hurricane Florence. I am planning this Women ... it while living out of a suitcase and knowing I have to hold onto ...
(Date:9/13/2018)... ... September 13, 2018 , ... The ultimate fitness experience has hit Astoria. A ... new arrival is called Form50 Fitness . , The studio practices the Lagree ... - a hybrid Pilates reformer with pulleys, weights, grasps and glides. The method and ...
Breaking Medicine Technology:
(Date:9/22/2018)... ... 2018 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... event held each year during Blood Cancer Awareness Month. , This year’s event ...
(Date:9/15/2018)... ... September 14, 2018 , ... Today, Mediaplanet announces the ... innovative work being done within rare diseases research, diagnostics, and will highlight what ... rare diseases. , Clay Matthews, Super Bowl-winning linebacker for the ...
(Date:9/13/2018)... , ... September 13, 2018 , ... ... honoring National Gum Care Month to educate their patients and the general public ... advanced equipment and procedures. Not only do Drs. Nash have extensive training in ...
(Date:9/13/2018)... ... , ... Pulsara is honored to be represented by its CEO, Dr. James ... in Chicago. Dr. Woodson, ER Physician and Founder/CEO of Pulsara, has been invited ... Communication & Collaboration (CC&C) is Not Enough: Why You Need a Regional Communication Network.” ...
(Date:9/12/2018)... ... September 12, 2018 , ... Today, Sterling , ... Maureen Beck, attempted the first unassisted adaptive climb of the Lotus Flower Tower in ... made it difficult for him to lead, the duo decided to persevere and with ...
Breaking Medicine News(10 mins):